type 2 diabetes mellitus
Conditions
Interventions
Divide in the preceding administration group and the trailing administered group. Preceding administration group to medication the SGLT2 inhibitor for about 12 weeks. After that, this group to abort
Sponsors
Dokkyo medical university, Endocrinology and Metabolism
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and women who were diagnosed with type 2 diabetes. Patients who are considered treatment with SGLT2 inhibitors is suitable. Patients who are obtained informed consent.
Exclusion criteria
Exclusion criteria: 1.Type 1 diabetes, secondary diabetes 2.Severe ketosis, diabetic coma, or before coma 3.Severe infection, before and not long after surgery, or patients with severe trauma 4.Severe cerebrovascular dysfunction, heart disorder, renal dysfunction and liver dysfunction 5.Heart failure(NYHA classification 3-4), patients treated by diuretic 6.Patients who have repeated urinary tract infections 7.Alchole intake excessive 8.Women suspected of pregnancy or pregnant 9.Patients with a history of use SGLT2 inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat Body composition Body weight Lipid Adipocytokine | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c Fasting plasma glucose Serum Insulin Glycogen Serum ketone body Urinary glucose excretion Urinary albumin Blood pressure | — |
Countries
Japan
Contacts
Public ContactMasaaki Sagara
Dokkyo medical university Endocrinology and Metabolism
Outcome results
None listed